Gut-liver interaction in triglyceride-rich lipoprotein metabolism
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The liver and intestine have complementary and coordinated roles in lipoprotein metabolism. Despite their highly specialized functions, assembly and secretion of triglyceride-rich lipoproteins (TRL; apoB-100-containing VLDL in the liver and apoB-48-containing chylomicrons in the intestine) are regulated by many of the same hormonal, inflammatory, nutritional, and metabolic factors. Furthermore, lipoprotein metabolism in these two organs may be affected in a similar fashion by certain disorders. In insulin resistance, for example, overproduction of TRL by both liver and intestine is a prominent component of and underlies other features of a complex dyslipidemia and increased risk of atherosclerosis. The intestine is gaining increasing recognition for its importance in affecting whole body lipid homeostasis, in part through its interaction with the liver. This review aims to integrate recent advances in our understanding of these processes and attempts to provide insight into the factors that coordinate lipid homeostasis in these two organs in health and disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · cited 1×
“The gut microflora has also recently been implicated in the etiology of obesity and metabolic syndrome (11, 172, 217).”
BackgroundInflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 1×
“Binding of apoE, present on the hydrolysis products of TRL to cell surface receptors (mainly in the liver, but also in the endothelial wall), represents the major pathway of remnant particle catabolism (127).”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“GLP-1 also slows gastric emptying, inhibits glucose-dependent glucagon secretion, and promotes satiety (12).”
BackgroundStanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase
Haemmerle, G., Lass, A., Zimmermann, R., Gorkiewicz, G., Meyer, C., Rozman, J., Heldmaier, G., Maier, R., Theussl, C., Eder, S., et al. (2006) · Science · doi:10.1126/science.1123965 · Cited by 1,375
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus
Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N. E., Ahfeldt, T., Sachs, K. V., Li, X., Li, H., Kuperwasser, N., Ruda, V. M., et al. (2010) · Nature · doi:10.1038/nature09266 · Cited by 1,140 · cited 1×
“Recently, sortilin-1 has been identified as an important regulator of VLDL secretion, although currently it is unclear whether it inhibits VLDL secretion (142) or serves as an intracellular sorting receptor in the trans-Golgi network to export VLDL (102).”
BackgroundDiabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Iqbal, J., & Hussain, M. M. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90899.2008 · Cited by 811
Overproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly
Hussain, M. M., Shi, J., & Dreizen, P. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r200014-jlr200 · Cited by 591 · cited 1×
“MTP is an ER membrane-associated chaperone responsible for the transfer of lipids (TG, phospholipids, and cholesterol ester) to nascent apoB-containing lipoprotein particles, which prevents the apoB from proteasome- and ERmediated degradation (91, 92).”
BackgroundInhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., Millar, J. S., Ikewaki, K., Siegelman, E. S., Gregg, R. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061189 · Cited by 580 · cited 2×
“Modulation of MTP activity significantly affects circulating apoB lipoproteins, thus MTP inhibitors were postulated to be beneficial for lipid lowering, especially for those unable to attain LDL-cholesterol targets or with familial hypercholesterolemia (44, 178).”
BackgroundDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 2×
“The signaling pathways activated by GLP-1R agonism ostensibly inhibit lipogenesis given the downregulation of ACC, SCD-1, SREBP-1c, and FAS mRNA, and promote -oxidation by increasing PPAR , AOX and CPT-1 mRNA (17, 52).”
BackgroundGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes
Ginsberg, H. N., Zhang, Y.-L., & Hernandez-Ono, A. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.005 · Cited by 531 · cited 1×
“In the presence of compromised metabolic conditions, such as insulin resistance, type 2 diabetes (T2D), and metabolic syndrome, a cluster of dyslipidemic characteristics are present, including hypertriglyceridemia, low highdensity lipoprotein (HDL), and small, dense low-density lipoprotein (LDL) particles (73).”
BackgroundParks, E. J., & Hellerstein, M. K. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.412 · Cited by 530
Brunzell, J. D., Hazzard, W. R., Porte, D., & Bierman, E. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107334 · Cited by 484 · cited 2×
“This is consistent with concomitant upregulation of hepatic LDL receptor with inhibition of intestinal cholesterol absorption (49) and competition for removal between apoB-48- and apoB-100-containing particles (25).”
BackgroundBiddinger, S. B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J. T., Alemán, J. O., Suzuki, R., Scapa, E. F., Agarwal, C., Carey, M. C., Stephanopoulos, G., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.013 · Cited by 469
Mora, S., Rifai, N., Buring, J. E., & Ridker, P. M. (2008) · Circulation · doi:10.1161/circulationaha.108.777334 · Cited by 445
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia
Johansen, C. T., Wang, J., Lanktree, M. B., Cao, H., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., et al. (2010) · Nature Genetics · doi:10.1038/ng.628 · Cited by 437
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.
Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M.-R. (1997) · Diabetologia · doi:10.1007/s001250050700 · Cited by 319
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · cited 2×
“First, GLP-1 profoundly slows gastric emptying and intestinal transit time in humans (134, 135); thus, the hypolipidemic effect of GLP-1R agonist may be at least partly due to decreased gastric emptying.”
BackgroundThe Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., Charron, M. J., & Drucker, D. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.008 · Cited by 272 · cited 2×
“In mice in the fasted state, glucagon, acting through the glucagon receptor, inhibits TG synthesis and secretion, activates AMPK, and subsequently activates PPAR , stimulating fatty acid -oxidation, thus limiting substrate supply for TG synthesis in the liver (124).”
BackgroundCohn, J. S., Johnson, E. J., Millar, J. S., Cohn, S. D., Milne, R. W., Marcel, Y. L., Russell, R. M., & Schaefer, E. J. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35345-1 · Cited by 248
Samaha, F. F., McKenney, J., Bloedon, L. T., Sasiela, W. J., & Rader, D. J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1250 · Cited by 220
Watts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
Cohn, J. S., McNamara, J. R., Cohn, S. D., Ordovas, J. M., & Schaefer, E. J. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38485-6 · Cited by 195
Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Schwartz, E. A., Koska, J., Mullin, M. P., Syoufi, I., Schwenke, D. C., & Reaven, P. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.028 · Cited by 173
Effect of Dietary Carbohydrate on Triglyceride Metabolism in Humans
Parks, E. J. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.10.2772s · Cited by 172
Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170
Karpe, F., Bell, M., Björkegren, J., & Hamsten, A. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.2.199 · Cited by 143 · cited 2×
“Whereas the TRL fraction consists mainly of hepatically derived apoB-100-containing very low-density lipoprotein (VLDL), intestinally derived apoB-48-containing chylomicrons contribute to postprandial TRL (100, 204).”
BackgroundPan, M., Maitin, V., Parathath, S., Andreo, U., Lin, S. X., Germain, C. S., Yao, Z., Maxfield, F. R., Williams, K. J., & Fisher, E. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707460104 · Cited by 128
Ayala, J. E., Bracy, D. P., James, F. D., Burmeister, M. A., Wasserman, D. H., & Drucker, D. J. (2010) · Endocrinology · doi:10.1210/en.2010-0289 · Cited by 95
Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives
Ginsberg, H. N. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90873-4 · Cited by 32 · cited 10×
“Following a meal, the majority of the chylomicron TG is sequestered by extrahepatic tissues (mainly adipose) following LPL lipolysis in the capillary microcirculation (19, 175).”
BackgroundInfluential
Cited by
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237
“21 They are composed of a neutral core of TG and cholesterol esters and a surface monolayer comprising phospholipids, free cholesterol, and apos, which participate in the regulation of transport and metabolism of the TRL. 22 The metabolism of TRLs occurs via two principal pathways, an exogenous pathway that originates…”
BackgroundRecent advances in physiological lipoprotein metabolism
Ramasamy, I. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0358 · Cited by 235
“Studies suggest that monosaccharides can acutely enhance intestinal lipoprotein particle production [326].”
BackgroundXiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
Self-citationNew insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194
Self-citationPostprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
Metadata
- Authors
- Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2011-09
- Volume
- 301
- Issue
- 3
- Pages
- E429-E446
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2158149431
- Cited by
- 127
- References
- 40
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.